Professor Geoff Donnan, director of the Florey, said, "The Florey is delighted that a groundbreaking piece of work from our scientists and collaborators has the opportunity to be partnered with Servier with the promise of new medicines being developed to treat Alzheimer's disease."
Dr Emmanuel Canet, president of Servier R&D, commented that Servier is dedicated to the research and development of novel therapeutic for the treatment of neurodegenerative and psychiatric diseases. "This collaboration between Servier and the Florey, Monash University and St Vincent's Institute brings together unique expertise in neurological and psychiatric disorders and drug discovery. This partnership reinforces our quest to find innovative drugs for Neurodegenerative Diseases such as Alzheimer's disease," he said.

Dr Bernard Marchand, general manager of the Institut de Recherche Servier, commented, "The Florey and its partners have made tremendous efforts in understanding the role of IRAP in the pathology of Alzheimer's disease. We consider that IRAP may have potential as a target of therapeutic importance in the development of neurodegenerative diseases and it is the task of this collaboration to validate this belief and provide a platform for the identification of novel therapeutic agents acting on IRAP."